




The relative strengths and weaknesses of Unicycive Therapeutics Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Unicycive Therapeutics Inc compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 15% points. The greatest weakness of Unicycive Therapeutics Inc is the variable Liabilities, Current, reducing the Economic Capital Ratio by 56% points.

The company's Economic Capital Ratio, given in the ranking table, is 135%, being 80% points below the market average of 215%.

Input Variable	Value in 1000 USD
Assets, Current	30,948
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	24,120
Liabilities, Non-Current	117
Other Assets	645
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	-4,612
Other Revenues	0
Property and Equipment	75
Research and Development	20,014
Selling, General and Administrative Expense	12,103

Output Variable	Value in 1000 USD
Assets	31,668
Liabilities	24,237
Expenses	32,117
Revenues	0
Stockholders Equity	7,431
Net Income	-36,729
Comprehensive Net Income	-36,729
BaseVar	46,317
ECR before LimitedLiability	-73%
Economic Capital Ratio	135%